ACRO has partnered with TransCelerate BioPharma to develop a new acceptable ranges considerations tool to support stakeholders’ internal development and implementation of acceptable ranges under the new ICH E6(R3) guideline.
The “Acceptable Ranges for Clinical Trials: Insights from ICH E6(R3)” toolkit dives into the introduction of acceptable ranges and comparison to E6(R2), key considerations and tips for implementation, and includes a case example.
